- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07836478
Neurocognitive Integrity After Proton Therapy for Brain Tumor (PROTON MIND)
Prospective Evaluation of Neurocognitive Integrity After Proton Therapy for Brain Tumor
Radiation therapy remains a cornerstone in the management of both benign and malignant intracranial tumors, either as monotherapy or combined with surgery and/or chemotherapy. Despite its therapeutic benefits, it is frequently associated with potential long-term adverse effects, with neurotoxicity posing a major challenge, especially in young patients affected by benign primary tumors.
연구 개요
상태
정황
상세 설명
In the brain, late radiotoxicities typically manifest as cognitive dysfunction, leukoencephalopathy, brain atrophy, brain tissue necrosis, cerebrovascular complications, endocrinopathies, and/or secondary malignant neoplasms.
Radiation-induced hippocampal injury, in particular, significantly contributes to cognitive impairment, while broader central nervous system effects arise through multiple mechanisms, including vascular injury, neuronal depletion, chronic inflammation, demyelination, and tissue necrosis.
The severity of cognitive dysfunction depends on multiple factors, including the location and the volume of the tumor, the total radiation dose administered, the fractionation regimen, and the individual susceptibility of the patient, as well as comorbidities (e.g., diabetes, etc.) and concomitant drugs.
The distinct physical characteristics of proton therapy, such as a reduced entrance dose, an eliminated exit dose, and a Bragg peak, provide clear dosimetric advantages over conventional photon treatments. Pencil-beam scanning further improves on earlier passive scattering approaches by delivering modulated proton beamlets for superior target conformality and reduced neutron scatter, thereby limiting low- and intermediate- dose exposure to cranial organs at risk (OARs) while preserving adequate dose coverage within the target volume.
From a radiobiological standpoint, these properties suggest that proton therapy may present a more favorable risk-benefit balance compared to photon-based modalities, particularly for long-term clinical outcomes. It achieves a drastic reduction in the integral dose, offering substantial benefit in decreasing radiation-induced second malignancies, making it mandatory for children when available.
Proton therapy is well established for treating pediatric tumors, CNS tumors such as low-grade gliomas (LGG) and meningiomas, especially if near the optic pathway or brainstem, and all the benign tumors in young patients. In these cases, the primary goal extends beyond curing the disease to preserving neurological and cognitive functions.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Gabriella Pravettoni
- 전화번호: +39 0257489207
- 이메일: Gabriella.Pravettoni@ieo.it
연구 장소
-
-
Italy
-
Milan, Italy, 이탈리아, 20141
- European Institute of Oncology, Milan
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients affected by primary central nervous system tumors and eligible for protontherapy as adjuvant or radical treatment
설명
Inclusion Criteria:
- Primary tumors of Brain Tumor (CNS), benign and malignant
- Age ≥ 18 years
- Patients able to speak and read the local language(s) fluently
- Acceptance and signature of informed consent
- Radiological diagnosis, biopsy, or previous surgery
- Concomitant medical therapy is allowed
Exclusion Criteria:
- Previous brain radiotherapy (any form)
- High-grade gliomas
- Patients with concomitant neurological or psychiatric disorders.
- Pregnancy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The presence of cognitive impairment
기간: From the end of Protontherapy through study completion, an average of 1 year.
|
The primary endpoint will be the presence of cognitive impairment during the first 5 years after enrollment, as measured by a comprehensive neuropsychological assessment. |
From the end of Protontherapy through study completion, an average of 1 year.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Perceived cognitive impairment
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Functional Assessment of Cancer Therapy-cognition (FACT-cog) 37 items will be completed (score 1-4) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Depressive symptoms
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
At Beck Depression Inventory-II (BDI-II) 21 items will be completed (score 0-3) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Anxiety
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For State-Trait Anxiety Inventory (STAI) 40 items will be completed (score 1-4) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Quality of Life data (QoL) - EORTC QLQ C30 questionnaires.
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For EORTC QLQ C30, 30 items will be completed (score 1-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Sleep quality
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Pittsburgh Sleep Quality Index (PSQI) 24 items will be completed (score 0-3) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Cognitive Reserve
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Cognitive Reserve Index questionnaire (CRIq) 20 items will be completed (core 0-1) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Global functioning
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Montreal Cognitive Assessment (MoCA) 30 items will be completed (score 1-5). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Learning and Verbal Memory
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey Auditory Verbal Learning Test (RAVLT) 15 items will be completed (score 0-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Working memory
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Corsi Span backward/forward 18 items will be completed (score 0-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Visual memory
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey-Osterrieth complex figure -recall 18 items will be completed (score 0-2). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Visuospatial abilities
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey-Osterrieth complex figure -copy 18 items will be completed (score 0-2). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Executive function
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Frontal Assessment Battery (FAB) 30 items will be completed (score 0-3). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Attention
기간: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Symbol digit modalities test (SDMT) 110 items will be completed (score 0-1) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- UID 5445
- L2-684 (기타 식별자: Comitato Etico Lombardia 2)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .